No significant drug−drug interaction between oral TAF‐based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT‐3 study

No significant drug−drug interaction between oral TAF‐based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT‐3 study

Abstract Introduction Concerns regarding potential drug−drug interaction (DDI) between feminizing hormone therapy (FHT) and HIV pre‐exposure prophylaxis (PrEP) may hinder PrEP use among transgender women. We assessed the potential DDI between FHT and emtricitabine‐tenofovir alafenamide (F/TAF)‐based...

Full description

Saved in:
Bibliographic Details
Main Authors: Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, Rena Janamnuaysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressey, Peter L. Anderson, Nittaya Phanuphak, the iFACT3 study team
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Journal of the International AIDS Society
Subjects:
drug−drug interactions
feminizing hormone therapy
HIV prevention
pre‐exposure prophylaxis
Thailand
transgender women
Online Access:https://doi.org/10.1002/jia2.26502
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items